Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes
RDEC
A Randomized Controlled Trial of Reduced Nicotine Cigarettes and E-cigarettes Among Dual Users
1 other identifier
interventional
308
1 country
2
Brief Summary
Cigarette smoking remains the leading cause of preventable morbidity and mortality in the US. Use of multiple tobacco products is becoming increasingly prevalent, with dual use of e-cigarettes and cigarettes representing the most common combination. Though e-cigarettes are not without risk, completely switching from cigarettes to e-cigarettes likely reduces risk for tobacco-related harm. However, many established dual users maintain long-term smoking and the majority who use e-cigarettes non-daily are at an even greater risk for prolonged smoking than exclusive cigarette smokers. The Food and Drug Administration Center for Tobacco Products (FDA CTP) has announced plans to implement a nicotine-limiting product standard, capping the nicotine in cigarettes at a minimally or non-addictive level. Randomized controlled trials (RCTs) demonstrate that adults who exclusively smoke cigarettes respond to very low nicotine content (VLNC) cigarettes with reductions in smoking, demand, and dependence. However, nicotine reduction RCTs to date have excluded people who regularly use e-cigarettes and therefore it remains unclear how a nicotine-limiting standard for cigarettes would affect smoking among dual users. Given the potential substitutability of e-cigarettes for cigarettes, reducing the nicotine in cigarettes could promote a transition to exclusive e-cigarette use among dual users unable to completely quit nicotine, but only if sufficiently appealing e-cigarettes remain available. E-cigarettes containing 5% nicotine-salt solution are currently most popular in the US, but policy makers have proposed restricting e-cigarettes to ≤ 2% nicotine to curb youth e-cigarette use, and several states have already set limits to reduce nicotine in e-cigarettes. Prior laboratory studies indicate that higher vs lower nicotine e-cigarettes serve as better substitutes for cigarettes among adult dual users. As such, a restriction on e-cigarette nicotine concentration could undermine the potential for e-cigarettes to substitute for cigarettes and diminish the benefits of a nicotine-limiting standard for cigarettes among dual users. This study is a 12-week double-blind 2 cigarette level (Normal Nicotine vs Very Low Nicotine) x 2 e-cigarette level (High Nicotine vs Low Nicotine) between-subjects factorial trial to investigate how a nicotine-limiting standard for cigarettes affects adult dual users and whether these effects are impacted by constraints on e-cigarette nicotine concentration. Outcome measures include cigarettes per day, cigarette dependence, and toxicant exposure. The research is highly relevant to FDA CTP domains of Addiction and Behavior because it will test whether reducing the nicotine content of cigarettes reduces smoking and dependence, and whether these effects are moderated by the availability of high vs low nicotine e-cigarettes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2
Started Nov 2024
Typical duration for phase_2
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 23, 2024
CompletedFirst Posted
Study publicly available on registry
September 26, 2024
CompletedStudy Start
First participant enrolled
November 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 30, 2028
June 27, 2025
September 1, 2024
3.8 years
September 23, 2024
June 23, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of cigarettes smoked per day
12 weeks
Study Arms (4)
RC 1 + REC 1
EXPERIMENTALResearch cigarettes #1 plus research e-cigarettes #1
RC 1 + REC 2
EXPERIMENTALResearch cigarettes #1 plus research e-cigarettes #2
RC 2 + REC 1
EXPERIMENTALResearch cigarettes #2 plus research cigarettes #1
RC 2 + REC 2
EXPERIMENTALResearch cigarettes #2 + research e-cigarettes #2
Interventions
Altering the nicotine content of the tobacco research cigarettes
Altering the nicotine content of the research e-cigarettes
Eligibility Criteria
You may qualify if:
- Regular use of tobacco
- year of age or older
- Speak, comprehend and read English well enough to complete study procedures
You may not qualify if:
- Pregnant, trying to become pregnant, or nursing
- Under the age of 21
- Health conditions that could undermine ability to complete the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Brown University
Providence, Rhode Island, 02903, United States
University of Vermont
Burlington, Vermont, 05405, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Elias Klemperer, PhD
University of Vermont
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- OTHER
- Intervention Model
- FACTORIAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
September 23, 2024
First Posted
September 26, 2024
Study Start
November 1, 2024
Primary Completion (Estimated)
August 31, 2028
Study Completion (Estimated)
September 30, 2028
Last Updated
June 27, 2025
Record last verified: 2024-09
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF
Data will be made available once we have published the results of the parent trials and manuscripts based on secondary analyses of those data, which we anticipate taking approximately three years.